Results 131 to 140 of about 393,653 (192)

Toll-like receptor 4 inhibition sensitizes non-small cell lung cancer to radiotherapy. [PDF]

Cancer Biol Ther
Haroun R, Rutihinda C, Diallo AH, Ordonez JP, Nassri S, Shams A, Pacheco MFM, Saidi NE, Bouchard L, Turgeon GA, Gris D, Tai LH, Oweida AJ.   +12 more
europepmc   +1 more source

STAT1 drives the immune landscape of murine Toll-like receptor 9-induced liver inflammation. [PDF]

JHEP Rep
De Visscher A, Beliën J, Bernaerts E, Vandeput M, Malengier-Devlies B, Prenen F, Meers H, Sokol L, Mitera T, Berghmans N, Anak S, Govaere O, Van den Steen P, Lamote J, Vandamme N, Bujko A, Scott CL, Wouters CH, Matthys P.   +18 more
europepmc   +1 more source

RETRACTION: Qi-Dong-Huo-Xue-Yin Inhibits Inflammation in Acute Lung Injury in Mice via Toll-Like Receptor 4/Caveolin-1 Signaling. [PDF]

Evid Based Complement Alternat Med
Alternative Medicine EC.
europepmc   +1 more source

Metabolic Reprogramming in Toll-like Receptor-Mediated Platelet Activation. [PDF]

Cells
Cheah LT, Khalil JS, McKay M, Ali M, Duval C, Unsworth AJ, Naseem KM.   +6 more
europepmc   +1 more source

Toll-like Receptor

Journal of Clinical and Experimental Hematopathology, 2011
openaire   +2 more sources

Polydatin alleviates mitochondrial damage and apoptosis of lung epithelial cells by inhibiting toll-like receptor 4-dependent macrophage activation in asthma. [PDF]

Animal Model Exp Med
Li G, Liu R, Xu C, Yang J, Song Y, Li L, Jiang J, Li L, Wang C, Yan G.   +9 more
europepmc   +1 more source

Association of Toll-like receptor signaling molecule gene polymorphisms with risk of cervical lesions in HPV-infected women. [PDF]

BMC Infect Dis
Wang S, Zhang C, Li T, Luo P, Yang Y, Lin Z, Mei B.   +6 more
europepmc   +1 more source

Absence of Toll-like Receptor 21 (<i>TLR21</i>) Gene in the Genome of Transparent Glass Catfish (<i>Kryptopterus vitreolus</i>). [PDF]

Biology (Basel)
Guo S, Zhang X, Zhang R, Zhang K, Chen J, Lv Y, Wen Z, Chen J, Bian C, Shi Q.   +9 more
europepmc   +1 more source

Dual-Action Theranostic Nanoparticles Delivering Toll-Like Receptor 2 Inhibitors and Chemotherapy Target Breast Cancer Cells and the Tumor Microenvironment. [PDF]

Int J Nanomedicine
Di Lorenzo A, Romiti C, Amaolo A, Cossu C, Iacoviello A, Curcio C, Forni M, Zanini C, Cavallo F, Ferrauto G, Di Gregorio E, Conti L.   +11 more
europepmc   +1 more source

Deficiency of Toll-like receptor 2 is a driver of sex-related compositional and structural rearrangements of membrane lipids. [PDF]

Commun Chem
Ica RS, Mlinac-Jerkovic K, Stojanović M, Roxana Biricioiu M, Puljko B, Maček-Hrvat N, Radmilović MD, Korade Ž, Mirnics K, Clemmer DE, Zamfir AD, Kalanj-Bognar S.   +11 more
europepmc   +1 more source